Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  4.00 0.31% 1,306.00 1,302.00 1,308.00 1,314.00 1,302.00 1,304.00 6,628 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 86.4 12.6 20.0 65.3 647

Ergomed Share Discussion Threads

Showing 1001 to 1020 of 1025 messages
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
DateSubjectAuthorDiscuss
14/10/2022
15:34
Octopus holdings {from my records}
piedro
10/10/2022
11:06
PrimeVigilance@PrimeVigilance
EVENT – Greetings from Tokyo! We are so pleased to be a first-time exhibitor
at the DIA Japan Annual Meeting.
If you are attending, look up Booth #19 and stop by to meet our team from our
regional hub in Tokyo.

piedro
27/9/2022
16:06
It is a service business
Productivity improvements are probably limited

phillis
27/9/2022
12:19
Updated chart ...



- that is what I wanted to see: cost growth moderated

piedro
27/9/2022
09:46
Another very impressive web-cast today.
ihatemms
26/7/2022
11:32
Ergomed cheers 'very strong' performance in first half of 2022

hTTps://www.youtube.com/watch?v=FpZVQuZlTUU

piedro
26/7/2022
09:54
Excellent update for interims and H2 outlook particularly order book. glad I topped up recently.
adorling
26/7/2022
09:47
Business as usual update,
but can they keep costs under control?

piedro
25/7/2022
11:22
let's see what tomorrow brings
mfhmfh
10/6/2022
07:18
Update looks good to me.
capitalist
29/3/2022
10:22
Includes £3m contingent earn out deemed employment cost
phillis
29/3/2022
07:08
Super results yet again - above expectations. This stock deserves a premium rating.
ihatemms
17/2/2022
17:27
...from last year...

Company overview:
Founded in 1997, Ergomed plc is a specialist services provider for the pharmaceutical industries, covering all phases of clinical development, post-approval pharmacovigilance and medical information. The company operates in more than 100 countries through its Pharmacovigilance and Clinical research Outsourcing service lines. The company has made several acquisitions over the past 5 years.
Last three years’ performance is categorized by steady growth in Revenue, gross Profit and adjusted EBITDA and order book growth in 2020 of 55.5%. Acquisition in 2020 was in the USA with ambition to increase market presence for both business lines. Revenue in USA is currently accounting for around 54%, compared to UK’s 14% and EU area 27%. Latest update from the company shows strong trade with 38% growth in revenue in the first half of the year bringing the interim figure to £56m. CRO division generated a staggering 90.7%. Healthy balance sheet and prospects for growth are firmly supported by increase in cash balance to £24.6m and growth in order book at 18% since 01/01/2021....from WealthOracleAM

https://wealthoracle.co.uk/detailed-result-full/ERGO/46

km18
09/2/2022
10:58
A boring acquisition
- £1.8m "adjusted" EBITDA for £25.6m
Can that be said to be a 7.0% ROCE?

I'm not an accountant but that does not seem very earnings enhancing
so hopefully the 'fringe' benefits ... more customers, offices etc
will be worthwhile

Also the webcast was dry and without enthusiasm.

AIMHO

piedro
03/2/2022
10:49
Might reach £16 one day but not this year
phillis
03/2/2022
05:21
Paul Jourdan of Amati Global talks positively about Ergomed here (starts 35:55)

www.youtube.com/watch?v=0nJJIpsI9Uo

brummy_git
25/1/2022
10:52
Great update from a great company.
blueflame
25/1/2022
09:20
Hi Guys,

I appreciate we're all a bit share shocked but this was an excellent trading update:

>> Adjusted EBITDA ahead of mkt expectations (1)

>> Revenue growth 37.3% (44.3% at constant currency)

>> US very strong growth 59.5% (71% at constant currency)

>> Throwing off cash.

And the Outlook is positive - order book is up 24% and in value is twice 2021 revenue. So, conversion should ensure strong growth continues.

Regards Maddox

(1) I wish they would state a figure for 'market expectations' - it's public domain so why not?

maddox
25/1/2022
07:46
Good trading update - business as usual

"Adjusted EBITDA for the year ended 31 December 2021 is expected to be ahead of current market expectations, reflecting the excellent operational execution and profit focus delivered across the business."

piedro
21/1/2022
11:27
On the contrary Way undervalued , the trading update ,next week will confirm my that.
bramble13
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
Your Recent History
LSE
ERGO
Ergomed
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221129 01:04:36